A1BG has been identified as an autoantigen in patients with rheumatoid arthritis and is overexpressed in rheumatoid arthritis, pancreatic ductal adenocarcinoma, bladder, breast and lung cancer, pediatric patients with steroid resistant nephrotic syndrome and liver cancer cell lines, suggesting that A1BG might be a cancer associated gene and a novel tumor marker (24, 25, 26, 27, 28, 29, 30). Here, A1BG is linked to neoplasm.